Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
October 27, 2023 08:00 ET
|
Belite Bio, Inc
Two-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presentedA two-year global Phase 3 trial in adolescent STGD1 (the “DRAGON”...
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
July 24, 2023 06:04 ET
|
Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry...
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
May 10, 2023 15:33 ET
|
Belite Bio, Inc
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal...